メルケル細胞がん:治療薬開発パイプライン分析

◆英語タイトル:Merkel Cell Carcinoma - Pipeline Review, H2 2017
◆商品コード:GMDHC10028IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年12月29日
◆ページ数:346
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるメルケル細胞がんの治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・メルケル細胞がんの概要
・メルケル細胞がん治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・メルケル細胞がんパイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・メルケル細胞がん治療薬開発に取り組んでいる企業:企業別製品パイプライン
・メルケル細胞がん治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Merkel Cell Carcinoma – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma – Pipeline Review, H2 2017, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 13, 10 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Merkel Cell Carcinoma – Overview 7
Merkel Cell Carcinoma – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Merkel Cell Carcinoma – Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 19
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Merkel Cell Carcinoma – Companies Involved in Therapeutics Development 26
Amgen Inc 26
Apcure SAS 26
BeiGene Ltd 26
Bristol-Myers Squibb Co 27
Checkpoint Therapeutics Inc 28
Exelixis Inc 28
F. Hoffmann-La Roche Ltd 29
Genentech Inc 29
Immune Design Corp 29
Merck & Co Inc 30
Merck KGaA 30
Millennium Pharmaceuticals Inc 31
NantKwest Inc 31
Novartis AG 32
OncoSec Medical Inc 32
Oncovir Inc 33
Ono Pharmaceutical Co Ltd 33
Philogen SpA 34
Tarveda Therapeutics Inc 34
Merkel Cell Carcinoma – Drug Profiles 35
APC-001 – Drug Profile 35
atezolizumab – Drug Profile 36
avelumab – Drug Profile 60
bevacizumab – Drug Profile 74
cabozantinib s-malate – Drug Profile 86
Cellular Immunotherapy 1 for Oncology – Drug Profile 109
Cellular Immunotherapy 2 for Oncology – Drug Profile 112
CK-301 – Drug Profile 114
G-100 – Drug Profile 116
ipilimumab – Drug Profile 121
ipilimumab + nivolumab – Drug Profile 132
MAL-3101 – Drug Profile 142
nivolumab – Drug Profile 143
pasireotide – Drug Profile 198
pasireotide ER – Drug Profile 202
pazopanib hydrochloride – Drug Profile 205
pembrolizumab – Drug Profile 214
PEN-221 – Drug Profile 280
Poly-ICLC – Drug Profile 282
RO-7198457 – Drug Profile 286
sapanisertib – Drug Profile 287
talimogene laherparepvec – Drug Profile 291
tavokinogene telseplasmid – Drug Profile 297
Teleukin – Drug Profile 309
tigilanol tiglate – Drug Profile 311
tislelizumab – Drug Profile 313
Vaccine to Target WT1 for Oncology – Drug Profile 318
Merkel Cell Carcinoma – Discontinued Products 319
Merkel Cell Carcinoma – Product Development Milestones 320
Featured News & Press Releases 320
Appendix 343
Methodology 343
Coverage 343
Secondary Research 343
Primary Research 343
Expert Panel Validation 343
Contact Us 343
Disclaimer 344

List of Tables
Number of Products under Development for Merkel Cell Carcinoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Merkel Cell Carcinoma - Pipeline by Amgen Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by Apcure SAS, H2 2017
Merkel Cell Carcinoma - Pipeline by BeiGene Ltd, H2 2017
Merkel Cell Carcinoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Merkel Cell Carcinoma - Pipeline by Checkpoint Therapeutics Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by Exelixis Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Merkel Cell Carcinoma - Pipeline by Genentech Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by Immune Design Corp, H2 2017
Merkel Cell Carcinoma - Pipeline by Merck & Co Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by Merck KGaA, H2 2017
Merkel Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by NantKwest Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by Novartis AG, H2 2017
Merkel Cell Carcinoma - Pipeline by OncoSec Medical Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by Oncovir Inc, H2 2017
Merkel Cell Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Merkel Cell Carcinoma - Pipeline by Philogen SpA, H2 2017
Merkel Cell Carcinoma - Pipeline by Tarveda Therapeutics Inc, H2 2017
Merkel Cell Carcinoma - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Merkel Cell Carcinoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

【レポートのキーワード】

メルケル細胞がん

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[メルケル細胞がん:治療薬開発パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆